University of Queensland (UQ) CSL Vaccine Candidate Description
The University of Queensland (UQ) CSL COVID-19 vaccine candidate (V451) combines the adjuvant technology MF59 to improve immune response, reduce the amount of antigen needed for each vaccine, and enable more doses to be manufactured more rapidly.
The UQ-CSL V451 developed a rapid response “molecular clamp” vaccine platform, a transformative technology patented by UniQuest, UQ’s technology transfer company that enables rapid vaccine design and production against outbreak viral pathogens.
Enveloped viruses have proteins on their surface that drive the fusion of the virus and host cell membranes, a key process in infection. These proteins are also the major target of a protective immune response.
Although they are able to induce an immune response, they are inherently unstable and can change shape when expressed on their own. This means that the immune response induced does not efficiently recognize the protein on the virus surface and so does not provide protection from subsequent infection.
UQ-CSL V451 has overcome this problem by using its proprietary “molecular clamp” technology that locks the unstable, prefusion version of the surface proteins in a form that allows the immune system to respond more effectively.
This is achieved using their proprietary “molecular clamp” technology that locks these proteins in their native virus surface form. This synthetic protein can then be purified and rapidly manufactured into a vaccine.
Most recently, early preclinical results of the UQ COVID-19 vaccine candidate showed that it produced high levels of antibodies that can neutralize the virus.
The next critical phase for The University of Queensland’s COVID-19 vaccine launched on July 13, 2020, with 120 adult volunteers receiving the first dose of the vaccine at the Brisbane clinic of phase 1 clinical trials specialist, Nucleus Network.
The Queensland Government has provided $10 million Advance Queensland funding for the vaccine project, the Federal Government has contributed $5 million and more than $10 million has been provided by philanthropic and other donors.
Should the Phase 1 study prove to be successful towards the end of 2020, CSL will take full responsibility for the subsequent Phase 2b/3 clinical trial, which is expected to commence in late 2020. CSL will further develop, manufacture, and distribute UQ’s COVID-19 vaccine candidate.
For more information about CSL Limited, visit www.csl.com.
University of Queensland (UQ) CSL Vaccine Candidate Indication
UQ-CSL V451 vaccine candidate is to prevent COVID-19 disease caused by infection with SARS-CoV-2.
Early preclinical trials showed that the UQ COVID-19 vaccine candidate produced high levels of antibodies that can neutralize the coronavirus.
University of Queensland (UQ) CSL Vaccine Candidate News
September 7, 2020 – CSL Limited announced it has signed a Heads of Agreement with the Australian Government for the supply of 51 million doses of the University of Queensland’s COVID-19 vaccine candidate (V451).
August 26, 2020 - Pre-clinical testing of The University of Queensland’s COVID-19 vaccine has produced positive indications about its potential effectiveness and manufacturability. Project co-leader Associate Professor Keith Chappell has reported to the International Society for Vaccines on data from animal trials conducted by Viroclinics-DDL in the Netherlands
July 13, 2020 - Healthy adult volunteers have received the first dose of the UQ-CSL V451 vaccine at the Brisbane clinic of phase 1 clinical trials specialist, Nucleus Network.
June 5, 2020 - CEPI and The University of Queensland announced that they have entered into a new, significant partnering agreement to accelerate the development, manufacture, and distribution of a COVID-19 vaccine candidate which has been pioneered by researchers at UQ.
April 29, 2020 - The University of Queensland’s COVID-19 vaccine candidate has shown the ability to raise high levels of antibodies that can neutralize the virus in early pre-clinical testing.
April 9, 2020 - The UQ vaccine development team will partner with the Dutch company, Viroclinics Xplore, on the crucial pre-clinical studies.
February 23, 2020 - A University of Queensland team has met a key milestone in their fast-tracked research to develop a vaccine for the coronavirus, COVID-19. In just 3-weeks, the team of researchers has created their first vaccine candidate in the laboratory and will move immediately into further development before formal pre-clinical testing.
January 24, 2020 - The Coalition for Epidemic Preparedness Innovations (CEPI) requested UQ use its rapid response vaccine technology to develop a vaccine, and the candidate being tested was produced within the first three weeks.
UQ COVID-19 Vaccine Candidate Clinical Trials
Launched in July 2020, the Phase 1 trial will involve about 120 volunteers aged between 18 and 55, will receive 2-doses on the UQ-CSL V451, with a proportion of participants to receive a placebo. The initial participant was dosed at the Brisbane Clinic.
The clinical batch of vaccine for use in the trial was manufactured in a close partnership between UQ and researchers at CSIRO’s advanced biologics production facility in Melbourne, with technical assistance from Australian biotech company CSL, Brisbane based Patheon, and the global biotech company Cytiva (formerly GE Life Sciences).
The UQ vaccine is expected to be available in 2021 should clinical trials be successful.